GSK to develop ofatumumab in autoimmune indications

Thursday 1 July 2010

GlaxoSmithKline Plc and Genmab A/S have altered their co-development agreement for ofatumumab (Arzerra) with the result that GSK will develop the antibody for autoimmune indications. The companies will continue their collaboration in cancer.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom